Lisa C. Costello-Boerrigter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lisa C. Costello-Boerrigter has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
Guido Boerrigter
Cardiorenal Research Laboratory, Mayo Clinic, Rochester, MN, USA
11 shared publications- John C. Burnett
Mayo Clinic
11 shared publications - Boerrigter
Department of Cardiology, Heart Center, Zentralklinik Bad Berka, Robert-Koch-Allee 9, 99437 Bad Berka, Germany
9 shared publications Alessandro Cataliotti
Cardiorenal Research Laboratory, Mayo Clinic, Rochester, MN, USA
6 shared publications- Denise M. Heublein
Mayo Clinic, Rochester, MN
6 shared publications - Richard J. Rodeheffer
Mayo Clinic, Rochester, MN
6 shared publications
Latest Publications
- Open Access
- 1 August 2011
- Published by Springer Nature in BMC Pharmacology
- Vol. 11 (S1) , P17
The novel dual GC-A and GC-B designer natriuretic peptide, cenderitide (CD-NP), enhances the renal actions of furosemide in a model of severe heart failure
- 1 August 2011
- Published by Springer Nature in BMC Pharmacology
- Vol. 11 (S1) , P17
Open AccessThe novel dual GC-A and GC-B designer natriuretic peptide, cenderitide (CD-NP), enhances the renal actions of furosemide in a model of severe heart failure
- Open Access
- 1 August 2011
- Published by Springer Nature in BMC Pharmacology
- Vol. 11 (S1) , 1-P18
Cenderitide (CD-NP), a novel peptide designed to activate both guanylyl cyclase B and A, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure in a proof-of-concept study in patients with chronic heart failure
- 1 August 2011
- Published by Springer Nature in BMC Pharmacology
- Vol. 11 (S1) , 1-P18
Open AccessCenderitide (CD-NP), a novel peptide designed to activate both guanylyl cyclase B and A, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure in a proof-of-concept study in patients with chronic heart failure
- Open Access
- 31 May 2011
- Published by Springer Nature in Nature Reviews Cardiology
- Vol. 8 (7) , 365-366
Furosemide—to DOSE or not to DOSE, that is the question
- 31 May 2011
- Published by Springer Nature in Nature Reviews Cardiology
- Vol. 8 (7) , 365-366
Open AccessFurosemide—to DOSE or not to DOSE, that is the question
- 1 March 2011
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 86 (3) , 210-218
The Effect of the Brain-Type Natriuretic Peptide Single-Nucleotide Polymorphism rs198389 on Test Characteristics of Common Assays
- 1 March 2011
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 86 (3) , 210-218
The Effect of the Brain-Type Natriuretic Peptide Single-Nucleotide Polymorphism rs198389 on Test Characteristics of Common Assays
- 31 August 2010
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 16 (8) , S4
A Genetic Variant of the ANP Gene Is Associated With a Lower Cardiometabolic Risk Profile in the General USA Population
- 31 August 2010
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 16 (8) , S4
A Genetic Variant of the ANP Gene Is Associated With a Lower Cardiometabolic Risk Profile in the General USA Population
- 31 August 2010
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 16 (8) , S14
Human Preclinical Systolic and Diastolic Dysfunction Is Characterized by Impaired Cardiorenal Endocrine Response to Acute Volume Overload
- 31 August 2010
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 16 (8) , S14
Human Preclinical Systolic and Diastolic Dysfunction Is Characterized by Impaired Cardiorenal Endocrine Response to Acute Volume Overload
- 31 August 2010
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 16 (8) , S76
Association of NPPA rs5065 Genetic Variant With Increased Cardiovascular Risk in the General USA Population
- 31 August 2010
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 16 (8) , S76
Association of NPPA rs5065 Genetic Variant With Increased Cardiovascular Risk in the General USA Population
- Open Access
- 1 May 2010
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 3 (3) , 412-419
Renal and Anti-Aldosterone Actions of Vasopressin-2 Receptor Antagonism and B-Type Natriuretic Peptide in Experimental Heart Failure
Background—: Hemodynamic and neurohumoral function can affect the efficacy of diuretic therapy in congestive heart failure. Arginine vasopressin increases water reabsorption through the V 2 receptor in the collecting duct, whereas B-type natriuretic peptide (BNP) decreases sodium reabsorption in the collecting duct. We hypothesized that combining BNP to the V 2 -receptor antagonist tolvaptan (TLV) would enhance renal excretory function by augmenting sodium excretion together with aquaresis without adversely affecting renal hemodynamics in experimental congestive heart failure. Methods and Results—: Congestive heart failure was induced in 3 groups (n=6 per group) of dogs by tachypacing. A acute experiment was done after 10 days. After baseline measurements, study groups received a 0.1 mg/kg IV bolus of TLV alone (TLV), TLV in combination with BNP (TLV+BNP; 50 ng/[kg · min]), or BNP alone (BNP). Mean arterial pressure increased with TLV, remained unchanged with TLV+BNP, and decreased with BNP (+5±1mm Hg versus −1±1 mm Hg versus −15±1 mm Hg; P P P P P <0.05). Conclusions—: Coadministration of TLV and BNP in experimental HF resulted in a beneficial profile of renal, neurohumoral, and hemodynamic actions, specifically potent diuresis with natriuresis, neutral effect on mean arterial pressure, and lack of aldosterone activation.
- 1 May 2010
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 3 (3) , 412-419
Open AccessRenal and Anti-Aldosterone Actions of Vasopressin-2 Receptor Antagonism and B-Type Natriuretic Peptide in Experimental Heart Failure
Background—: Hemodynamic and neurohumoral function can affect the efficacy of diuretic therapy in congestive heart failure. Arginine vasopressin increases water reabsorption through the V 2 receptor in the collecting duct, whereas B-type natriuretic peptide (BNP) decreases sodium reabsorption in the collecting duct. We hypothesized that combining BNP to the V 2 -receptor antagonist tolvaptan (TLV) would enhance renal excretory function by augmenting sodium excretion together with aquaresis without adversely affecting renal hemodynamics in experimental congestive heart failure. Methods and Results—: Congestive heart failure was induced in 3 groups (n=6 per group) of dogs by tachypacing. A acute experiment was done after 10 days. After baseline measurements, study groups received a 0.1 mg/kg IV bolus of TLV alone (TLV), TLV in combination with BNP (TLV+BNP; 50 ng/[kg · min]), or BNP alone (BNP). Mean arterial pressure increased with TLV, remained unchanged with TLV+BNP, and decreased with BNP (+5±1mm Hg versus −1±1 mm Hg versus −15±1 mm Hg; P P P P P <0.05). Conclusions—: Coadministration of TLV and BNP in experimental HF resulted in a beneficial profile of renal, neurohumoral, and hemodynamic actions, specifically potent diuresis with natriuresis, neutral effect on mean arterial pressure, and lack of aldosterone activation.
- 1 October 2009
- Published by Elsevier in Heart Failure Clinics
- Vol. 5 (4) , 501-514
Natriuretic Peptides in the Diagnosis and Management of Chronic Heart Failure
- 1 October 2009
- Published by Elsevier in Heart Failure Clinics
- Vol. 5 (4) , 501-514
Natriuretic Peptides in the Diagnosis and Management of Chronic Heart Failure
- 31 August 2009
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 15 (6) , S85
Chronic Renal Insufficiency: Prevalence in the General Population and Improved Detection of Cardiac Disease in Combination with BNP Assays
- 31 August 2009
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 15 (6) , S85
Chronic Renal Insufficiency: Prevalence in the General Population and Improved Detection of Cardiac Disease in Combination with BNP Assays